Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 4, 2003 - Issue 2
Submit an article Journal homepage
115
Views
13
CrossRef citations to date
0
Altmetric
Review

Anti-cocaine vaccines: antibody protection against relapse

Kathleen M Kantak Department of Psychology, Boston University, 64 Cummington St, Boston, Massachusetts, USA
Pages 213-218 | Published online: 02 Mar 2005

Bibliography

  • BONESE KF, WAINER BH, FITCH FW et al.: Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature1 (1974) 252:708–710.
  • ••First report of a vaccine against an illicitdrug.
  • OWENS SM, MAYERSOHN M: Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs. Drug Metab. Dispos. (1986) 14:52–58.
  • SUBSTANCE ABUSE & MENTAL HEALTH SERVICES ADMINISTRATION: 2000 National Household Survey on Drug Abuse.
  • CARROLL Fl, HOWELL LL, KUHAR MJ: Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J. Med. Chem. (1999) 42:2721–2736.
  • O'LEARY G, WEISS RD: Pharmacotherapies for cocaine dependence. Carr. Psychiatry Rep. (2000) 2:508–513.
  • HIEDA Y, KEYLER DE, VANDEVOORT JT et al: Active immunization alters the plasma nicotine concentration in rats. Pharmacol Exp. Ther. (1997) 283:1076–1081.
  • DE VILLIERS S, LINDBLOM N, KALAYANOV G et al.: Active immunisation against nicotine can suppress the nicotine-induced stimulation of brain dopaminergic reward pathways. Soc. Neurosci. Abstr. (2000) 26\(Part 1):529(Abstract 192.12).
  • ISOMURA S, WIRSCHING P, JANDA KD: An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis. J. Org. Chem. (2001) 66:4115–4121.
  • BYRNES-BLAKE KA, CARROLL Fl, ABRAHAM P et al.: Generation of anti-(+)methamphetamine antibodies is not impeded by Hmethamphetamine administration during active immunization of rats. Int. Lumina Pharmacol (2001) 1:329–338.
  • AKBARZADEH A, MEHRABY M, ZARBAKHSH M et al: Design and synthesis of a morphine-6-succinyl-bovine serum albumin hapten for vaccine development. Biotechnol Appl. Biochem. (1999) 30:139–145.
  • LANDRY DW, ZHAO K, YANG GX-Q et al: Antibody-catalyzed degradation of cocaine. Science 259:1899-1901.First report of catalytic antibodies against cocaine.
  • ROITT I, BROSTOFF J, MALE D:Immunology 6th Edition (2001) Mosby, London.
  • ALTMAN J, EVERITT BJ, GLAUTIER S et al.: The biological, social and clinical bases of drug addiction: commentary and debate. Psychopharmacol. (1996) 125:285–345.
  • BAGASRA 0, FORMAN LJ,HOWEEDY A et al.: A potentialvaccine for cocaine abuse prophylaxis. Immmunopharmacology(1992) 23:173–179.
  • ••First report of a vaccine against cocaine.
  • ETTINGER RH, ETTINGER WF, HARLESS WE: Active immunization with cocaine-protein conjugate attenuatescocaine effects. Pharmacol. Biochem. Behav. (1997) 58:215–220.
  • JOHNSON MW, ETTINGER RH: Active cocaine immunization attenuates the discriminative properties of cocaine.Exp. Clin. Psychopharmacol. (2000) 8:63–67.
  • CARRERA MRA, ASHLEY JA, PARSONS LH et al.: Suppression of psychoactive effects of cocaine by active immunization. Nature (1995) 378:727–730.
  • ••First report to demonstrate that a cocainevaccine can blunt the psychomotor stimulant effects of cocaine.
  • CARRERA MRA, ASHLEY JA, ZHOU B et al.: Cocaine vaccines: antibody protection against relapse in a rat model. Proc. Natl. Acad. Sci. USA (2000) 97:6202–6206.
  • CARRERA MR, ASHLEY JA,WIRSCHING P et al.: A second-generation vaccine protects against the psychoactive effects of cocaine. Proc. Natl. Acad. Sci. USA (2001) 98:1988–1992.
  • SCHABACKER DS, KIRSCHBAUM KS, SEGRE M: Exploring the feasibility of anti-idiotypic cocaine vaccine: analysis of the specificity of anti-cocaine antibodies (Abl) capable of inducing Ab213 anti-idiotypic antibodies. Immunology (2000) 100:48–56.
  • FOX BS, KANTAK KM, EDWARDS MA et al.: Efficacy of a therapeutic cocaine vaccine in rodent models. Nat. Medicine (1996) 2:1129–1232.
  • •Paper highlights the pharmacokinetic characteristics of IPC 10–10.
  • EVANS SM, CONE EJ,HENNINGFIELD JE: Arterial and venouscocaine plasma concentrations in humans:relationship to route of administration, cardiovascular effects and subjective effects. Pharmacol. Exp. Ther. (1996) 279:1345–1356.
  • KANTAK KM, COLLINS SL, LIPMAN EG et al.: Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (2000) 148:251–262.
  • •Paper highlights the pharmacodynarnic characteristics of IPC 10–10.
  • KANTAK KM, COLLINS SL, BOND J et al.: Time course of changes in cocaine self-administration behavior during immunization with the cocaine vaccine IPC-1010. Psychopharmacology (2001) 153:334–340.
  • KOSTEN TR, ROSEN M, BOND J et al: Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine (2002) 20:1196–1204
  • ••First clinical trial with a vaccine against adrug of abuse.
  • WASHTON AM, STONE-WASHTON N: Abstinence and relapse in outpatient cocaine addicts. J. Psychoactive Drugs (1990) 22:135–147.
  • SONG N, PARKER RB, LAIZURE SC: Cocaethylene formation in rat, dog and human hepatic microsomes. Life Sci. (1999) 64:2101–2108.
  • MCCANCE-KATZ EF, KOSTEN TR, JATLOW P: Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either alone - a multiple-dose study. Biol. Psychiatry (1998) 44:250–259.
  • RAVEN MA, NECESSARY BD, DANLUCK D et al.: Comparison of the reinforcing and anxiolytic effects of intravenous cocaine and cocaethylene. Exp. Clin. Psychopharmacol. (2000) 8:117–124.
  • MCKAY JR, ALTERMAN Al,RUTHERFORD MJ et al: Therelationship of alcohol use to cocaine relapse in cocaine dependent patients in an aftercare study. J. Stud Alcohol. (1999) 60:176–180.
  • BERGMAN J, KAMIEN JB,SPEALMAN RD: Antagonism of cocaine self-administration by selective dopamine D1 and D2 antagonists. Behav. Pharmacol (1990) 1:355–363.
  • CAINE SB, KOOB GF: Effects of dopamine D-1 and D-2 antagonists on cocaine self-administration under different schedules of reinforcement in the rat.Pharmacol. Exp. Ther: (1994) 270:209–218.
  • BORDNICK PS, SCHMITZ JM: Cocaine craving: an evaluation across treatment phases. J. Subst. Abuse (1998) 10:9–17.
  • KUHAR MJ, CARROLL Fl, BHARAT N et al.: anti-cocaine catalytic antibodies have no affinity for RTI compounds: Implications for treatment. Synapse (2001) 41:176–178.
  • ••first report to evaluate antibodies againstcocaine with other potential treatment medications.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.